The immune checkpoint inhibitor pembrolizumab may reduce this risk. New research findings are summarized in a short video.

At the final analysis, the coprimary endpoint of overall survival was not met. Topline data were announced from a phase 3 trial evaluating pembrolizumab (Keytruda ®) plus lenvatinib (Lenvima ...